 Dopamine turnover is decreased in the various brain regions of zonisamide-treated mice.
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Introduction
Parkinson's disease (PD) is a neurodegenerative disorder characterized by selective dopaminergic neuron loss in the substantia nigra and motor as well as non-motor impairment. Although the pathogenesis of PD remains unclear and disease-modifying therapies are not yet available, several novel drugs have been developed for symptomatic therapy.
Zonisamide (1,2-benzisoxazole-3-methanesulfonamide, ZNS) is one of such drugs. ZNS is initially used as an anti-convulsant drug (Arzimanoglou and Rahbani, 2006) and later found to be also effective in PD (Murata et al., 2007; Murata et al., 2001) . ZNS significantly improves the Unified Parkinson's Disease Rating Scale Part III score and reduces off-time in advanced PD patients (Murata et al., 2007; Murata et al., 2001) .
ZNS is currently approved as an anti-PD drug in Japan.
Although ZNS is effective in PD patients, the precise sites of action are largely unknown. Recently, various studies have shown that ZNS has multifunctional neuroprotective effects (Grover et al., 2013) . For example, in cell culture experiments, ZNS increases antioxidant manganese superoxide dismutase (MnSOD) (Kawajiri et al., 2010) and glutathione (Asanuma et al., 2010) . Also, ZNS inhibits production of reactive oxygen species, activation of caspase-3, apoptosis, and endoplasmic reticulum stress (Omura et al., 2012) . In animal models, administration of ZNS protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in mice and marmosets (Choudhury et al., 2010; Yokoyama et al., 2010) . Increased dopamine (DA) levels due 4 to up-regulation of tyrosine hydroxylase (TH) or decreased DA turnover in the striatum by ZNS administration (Yabe et al., 2009 ) may be responsible for motor improvement in these MPTP-treated models (Yokoyama et al., 2010) . Thus, ZNS may protect neurons by reducing various types of stress and act as an anti-Parkinsonism drug by changing DA metabolism. However, the actions of ZNS in vivo are still unclear.
To clarify the actions of ZNS in vivo, we administered ZNS to mice chronically and analyzed neurotransmitter metabolism and behaviors. We found that the amount of DA in ZNS-treated mice was increased and the amount of 3,4-dihydroxyphenylacetic acid (DOPAC) was decreased, resulting in decreased DA turnover in the striatum.
Behavioral analysis revealed that chronic administration of ZNS increased locomotor activity and novelty seeking. We also showed that ZNS significantly inhibited monoamine oxidase (MAO) activity in primary neurons and astrocytes. Taken together, these results indicate that ZNS suppresses DA turnover by inhibiting MAO activity and increases locomotor activity and novelty seeking.
Materials and Methods

Reagents and antibodies
ZNS was a gift from Sumitomo Dainippon Pharma. Anti-TH and anti-tubulin were purchased from Millipore (Billerica, MA, USA) and Sigma (Saint Louis, MO, USA), respectively.
Mice
5
Male C57BL/6J mice were purchased from SHIMIZU Laboratory Supplies (Kyoto, Japan). All the experiments with mice were carried out according to the guidelines for animal use and care of Kyoto University.
Administration of ZNS
One batch of mice (n = 3-6, respectively) is administered ZNS or vehicle in the diet for 4 month (from 2 to 6 m.o.), and analyzed with biochemical and immunohistochemical analysis. Mice were housed individually, and fed with CE-2 mash (CLEA Japan, Tokyo, Japan) or CE-2 mash plus ZNS (700 mg/kg/week, for an average of 100 mg/kg/day). Once a week, we measured the body weights of each mouse and changed the amount of ZNS in the mash. Another batch of mice (n = 9-11, respectively) is administered ZNS or vehicle from 2 m.o. to the end of behavioral test (Fig. 1) .
Preparation of samples from mice
Mice were sacrificed and perfused with cooled PBS. The brains were then removed and dissected into regions of interest. Brain samples were weighed, rapidly frozen with liquid nitrogen, and stored at −80°C until assayed. 
Measurement of neurotransmitters
Immunohistochemistry
Brains were fixed by perfusion with 4% phosphate-buffered paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 6 µm. Sections were stained with TH antibody (1:200, AB152, Millipore), followed by development using HISTOFINE for rabbit primary antibodies (Nichirei Biosciences Inc., Tokyo, Japan) and a metal-enhanced diaminobenzidine substrate kit (34065, Thermo Fisher Scientific, Waltham, MA, USA).
Open field test
The open field test was assessed using an open field instrument (Accuscan Instruments, Columbus, OH, USA). Mice were placed at the center of an open field of 40 × 40 × 30 cm, and the total traveling distance, the time spent in the center area, the vertical activity, and the stereotypic movements were recorded for 2 h.
Light-dark transition test
The light-dark transition test was performed as described previously (Nakajima et al., 2008) . Briefly, the apparatus used for the light-dark transition test consisted of a cage (21 × 42 × 25 cm) divided into two sections of equal size by a partition with a door (Ohara & Co., Tokyo, Japan). One chamber was brightly illuminated (390 lux), whereas the other chamber was dark (2 lux). Mice were placed into the dark area and allowed to move freely between the two chambers through the open door for 10 min. The total 7 number of transitions and time spent on each side were recorded. Entry of the mouse's entire body to the other chamber was regarded as one entry.
Crawley's sociability and social novelty preference test
The Crawley's sociability and social novelty preference test was performed as described previously (Umemori et al., 2013) . Briefly, a three-chambered box (each chamber was 20 × 40 × 22 cm) with dividing walls was made with small square openings (5 × 3 cm) that allowed access into each chamber. The day before the behavioral test, subject mice were placed in the center chamber and habituated for 10 min with two empty wire cup-like containers placed on the both side chambers. On the day of behavioral test, all the cages containing mice were transferred into the behavioral room at least 30 min before the first trial begins. To perform the sociability test, an unfamiliar male C57BL/6J mouse (stranger 1) was enclosed in a wire cup-like container of one of the side chambers. The location of stranger 1 in the left vs. right side chamber was systematically alternated between trials. To perform the social test, the subject mouse was first placed in the middle chamber and allowed to explore the entire the box for a 10-min session. The amount of time spent in each chamber was measured. Each mouse was tested in a 10-min session to quantify social preference for the first stranger. After the first 10-min session, to perform the preference for social novelty test, a second unfamiliar mouse (stranger 2) was placed in the chamber that had been empty during the first 10-min session. This second stranger was also enclosed in an identical wire cup-like container. The test mouse thus had a choice between the stranger 1 and stranger 2. The amount of time spent in each chamber during the second 10 min was measured as described above. 
Immunoblotting
Samples were suspended in triton X-100 buffer (1% triton X-100, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1× protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and sonicated. The samples were then centrifuged at 20,400 ×g for 15 min. The supernatants were used for SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore). The membrane was incubated with the appropriate primary antibodies, followed by incubation with a horseradish peroxidase-conjugated anti-rabbit IgG (Santa Cruz, Dallas, TX, USA). Immunoreactive proteins were visualized using ChemiLumi One (Nacalai Tesque) and an LAS4000 scanning system (Fuji Film, Tokyo, Japan).
Cell culture
Mouse primary neurons were obtained from the cerebral cortices of fetal mice at E14
and cultured in neurobasal medium (21103049, Thermo Fisher Scientific) supplemented with B-27 (17504044, Invitrogen, Carlsbad, CA, USA), 2mM L-glutamine (16948-04, Nacalai Tesque), and 1% penicillin-streptomycin (Thermo Fisher Scientific). Mouse primary astrocytes were obtained from the cerebral cortices of neonatal mice at P1 and cultured in Dulbecco's modified Eagle medium (DMEM, 043-30085, Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (GibcoQualified FBS, Thermo
Fisher Scientific), and 1% penicillin-streptomycin (Thermo Fisher Scientific). activity, the MAO-B reaction buffer was used.
Measurement of MAO activity
Data analysis
Data were analyzed using R statistical package (www.r-project.org) and are presented as the mean ± SD for MAO activity analysis and mean ± SEM for the other analyses.
Normally distributed population was evaluated using F-test. 
Results
ZNS inhibits DA turnover in mouse brain
To clarify the pharmacological actions of ZNS in vivo, we orally administered ZNS to mice for 4 months and measured the levels of DA and its metabolites in various brain regions. In ZNS-treated mice, DA levels were marginally increased in the striatum (F = 0.77, p = 0.072) and in the midbrain (F = 0.42, p = 0.062) ( Fig. 2A) . DA is metabolized to DOPAC by MAO and DOPAC is metabolized to homovanillic acid (HVA) by catechol-O-methyltransferase (COMT). DA is also metabolized to 3-methoxytyramine (3-MT) by COMT and 3-MT is metabolized to HVA by MAO (Bortolato et al., 2008) .
We also measured DOPAC and HVA levels in various brain regions. DOPAC levels were significantly decreased in the striatum (F = 0.89, *p = 0.017) and the hippocampus (F = 0.62, *p = 0.019), and marginally decreased in the pons (F = 0.14, p = 0.057).
HVA levels were significantly decreased in the olfactory bulb (F = 0.77, *p = 0.022) and the striatum (F = 0.12, *p = 0.049), and marginally decreased in the pons (F = 0.02, p = 0.059). ( Fig. 2A and Fig. S1A ). These data suggest that chronic administration of ZNS marginally increases DA levels and decreases DOPAC and HVA levels in various brain regions Next, we measured DA turnover, which is an important factor determining DA availability. If DA turnover is decreased, the DA content in synaptic clefts is increased.
We calculated DA turnover by measuring the ratios of DOPAC to DA and HVA to DA, and found that the DOPAC/DA ratio was significantly decreased in the striatum (F = 0.84, *p = 0.021), the frontal cortex (F = 0.11, *p = 0.034), the hippocampus (F = 0.84, *p = 0.031), and the pons (F = 0.09, *p = 0.047), and marginally decreased in midbrain (F = 0.34, p = 0.052) in ZNS-treated mice compared with untreated mice (Fig. 2B and (Fig. S3 ). These data suggest that ZNS suppresses DA turnover and slightly suppress 5-HT turnover in mouse brains.
One of the determinants of DA levels is DA synthesis. Thus, we measured the amount of TH in the striatum using immunoblotting and in the midbrain using immunohistochemistry. However, no significant changes were found between untreated mice and ZNS-treated mice ( Fig. S2A and S2B ), suggesting that ZNS does not up-regulate TH expression in mice.
ZNS increases locomotor activity and preference for social novelty in mice
Next, we examined the effects of ZNS on mice behaviors because ZNS improves various PD-related symptoms (Murata, 2004 (Murata, , 2010 ).
First, we performed an open field test and found no significant difference in anxiety behavior between untreated mice and ZNS-treated mice (distance, p = 0.118; stereotypic counts, p = 0.173; vertical activity, p = 0.766; center time, p = 0.374) (Fig. 3A, 3C , 3E, and 3F). However, the total distance traveled during the test was significantly increased 12 in the ZNS-treated mice (F = 0.94, *P = 0.023) (Fig. 3B) . Similarly, the total stereotypic count was increased in the ZNS-treated mice (F = 0.58, *P = 0.030) (Fig. 3D) . These results suggest ZNS increased locomotor activity (Tatem et al., 2014) .
Second, we performed the light-dark transition test. The traveling distances in both dark and light chambers were significantly increased in ZNS-treated mice (dark chamber, F = 0.13, *p = 0.028; light chamber, F = 0.23, *p = 0.043) (Fig. 4A and 4B ). The number of transitions between the two chambers was also increased in ZNS-treated mice (F = 0.97, *p = 0.044) (Fig. 4C) . The spent time in each chamber and the latency to enter the light chamber were not significantly different between ZNS-treated and untreated mice (dark chamber, F = 0.01, p = 0.656; light chamber, F = 0.01, p = 0.643; latency to enter the light chamber, F = 0.99, p = 0.908) (Fig. 4D, 4E , and 4F).
Finally, we performed Crawley's test of sociability and preference for social novelty.
These tests can assess social interactions independently of locomotor activity (Tanda et al., 2009) (Fig. 4G and 4H ). Next, we compared the preference for social novelty by comparing stay time and number of entries in the cage with a familiar vs. a stranger cage ( Fig. 4I and 4J ). In this preference for social novelty test, compared to untreated mice, ZNS-treated mice tended to spend more time in the cage with a stranger mouse (familiar vs stranger, untreated mice, F = 0.67, p = 0.95; familiar vs stranger, ZNS-treated mice, F = 0.75, *p = 0.030; untreated vs ZNS-treated 13 mice, stranger, F = 0.08, **p = 0.004) (Fig. 4I) . ZNS-treated mice tended to enter the cage with a stranger mouse more often than a cage with a familiar mouse (familiar vs stranger, ZNS-treated mice, F = 0.87, p = 0.078; untreated vs ZNS-treated mice, stranger, F = 0.54, p = 0.074) (Fig. 4J) . These data suggest that ZNS-treated mice prefer novelty more than untreated mice.
ZNS inhibits MAO activity in primary neurons and primary astrocytes
Because DA turnover was decreased in ZNS-treated mice (Fig. 2) , we hypothesized that ZNS may inhibit MAO activity. MAO metabolizes DA, and inhibition of MAO increases the amount of DA (Bortolato et al., 2008) . Two isozymes of MAO are expressed, MAO-A and MAO-B (Bortolato et al., 2008; Shih et al., 1999) . MAO-A is mainly, but not exclusively, located in brain neurons (Riederer et al., 1987) and MAO-B is almost exclusively expressed in astrocytes and serotonin-containing neurons (Levitt et al., 1982) in the central nervous system. Therefore, we examined both MAO-A and MAO-B activities in the primary neurons and astrocytes. In the mouse primary neurons, both MAO-A and -B were inhibited by ZNS in a dose-dependent manner ( Fig. 5A and 5B). ZNS inhibited MAO-A more than MAO-B in the primary neurons ( Fig. 5A and 5B). On the other hand, in mouse primary astrocytes, both MAO-A and -B were equally inhibited by ZNS in a dose-dependent manner ( Fig. 5C and 5D ).
Discussion
ZNS is used to improve PD symptoms and has been shown to play multiple neuroprotective roles (Grover et al., 2013 ). Here we show that ZNS marginally increased DA levels in the striatum and the mid brain, and inhibited DA turnover in the 14 various regions of mice. Although ZNS has been reported to up-regulate TH and activate DA synthesis in MPTP-treated mice (Yabe et al., 2009 ), we did not observe up-regulation of TH in mice in the striatum or midbrain, which contain dopaminergic neurons (Fig. S2) . The difference in duration of ZNS administration may account for this inconsistency because up-regulation of TH was only observed in acute stress conditions. Rather, the decreased ratios of DOPAC/DA and HVA/DA by ZNS suggest suppression of DA degradation.
To examine the effect of decrease in DA turnover on locomotor and psychophysiological performances, we performed behavioral analysis on untreated mice and ZNS-treated mice. First, we performed open field test and found that ZNS treatment did not affect anxiety in mice. However, the total distance all traveled during the test and the total stereotypic count were significantly increased in the ZNS-treated mice, which suggest ZNS increased locomotor activity (Tatem et al., 2014) . Next, we performed light-dark transition test and found that the traveling distances in both dark and light chambers, and the number of transitions between the chambers were increased in the ZNS-treated mice. Although light-dark transition test is usually used as anxiety testing, no significant differences were found in the latency to enter the light chamber between the untreated mice and ZNS-treated mice. The increased traveling distances in both dark and light chambers and the number of transition suggest increased locomotor activity, which is consistent with the results of open field test. DA levels in the striatum are one of the most important determinants of locomotion. An increase in intrasynaptic DA and activated DA signaling due to the suppression of DA turnover (Gainetdinov 2008; Gainetdinov et al., 2002) may have led to the hyperactive phenotypes in ZNS-treated mice. Therefore, these effects may contribute to the increased locomotor 15 by ZNS. Finally, we assessed sociability and social novelty preference. The preference for social novelty was significantly increased ZNS-treated mice. Given that PD patients have reported to have apathy with loss of interest in others and indifference of social interactions (Chaudhuri and Schapira, 2009 ), ZNS may be effective for improving such apathy and social interactions. The untreated mice exhibited no significant social preference and social novelty preference during the test, and ZNS-treated mice exhibited no significant social preference in the first 10 min of the test. This might be ascribed to the protocol of habituation. The subjected mice in the current study were habituated for 10 min the day before the test but not on the day of the test (Kaidanovich-Beilin O et al., 2011) . With this protocol, those results were sometimes observed (Umemori et al, 2013) .
A previous report showed that social behavior is altered in dopamine transporter knockout mice (Spielewoy et al., 2000) . In addition, midbrain dopamine receptor availability is inversely associated with novelty seeking traits in humans (Zald et al., 2008) , and dopamine modulates novelty seeking behavior in monkeys (Costa et al., 2014) . Enhanced novelty seeking responses are increased in MAO-B knockout mice (Bortolato et al., 2009) , and MAO-A variable number tandem repeat polymorphism affects novelty seeking in human (Shiraishi et al., 2006) . Based on these studies, ZNS might influence novelty seeking by inhibiting MAO activities and modulating dopaminergic signaling in mice. Indeed, ZNS suppressed both MAO-A and MAO-B activities in primary neurons and astrocytes, suggesting decreased DA turnover resulted from inhibition of MAO activity. MAO-A preferentially oxidizes DA, 5-TH and norepinephrine, whereas MAO-B preferentially oxidizes phenylethylamine as well as DA. (Shih et al., 1999) . Similar to DA turnover, 5-TH turnover was tended to be 16 decreased by ZNS treatment (Fig. S3) , suggesting ZNS might improve non-motor performances not only through modulating DA systems but also non-DA systems.
In conclusion, chronic administration of ZNS increased social interaction in mice mainly via inhibition of MAO activity and DA turnover. These results suggest that ZNS has positive effects not only on motor symptoms but also on neuropsychiatric non-motor symptoms such as loss of interest in PD patients.
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